Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multifield radiotherapy versus IV rituximab for indolent primary cutaneous B-cell lymphoma
2009-017401-11Phase 3Completed
- Sponsor
- CHU de Reims
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in cutaneous B-cell lymphoma (CBCL), primary cutaneous follicle center lymphoma (PCFCL) and cutaneous marginal zone lymphoma (PCMZL) (2 arms), sponsored by CHU de Reims. Primary endpoint: Disease-free survival. Started Jan 2011; status: completed.
02
Drugs
rituximab
03
Conditions
cutaneous B-cell lymphoma (CBCL)primary cutaneous follicle center lymphoma (PCFCL)cutaneous marginal zone lymphoma (PCMZL)
Beyond the preview
Go deeper on 2009-017401-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017401-11.